Karyopharm Therapeutics CAO Executes Pre-Planned Stock Sale Amid Strong 2025 Revenue Performance
Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc., sold 265 shares of the company's stock on January 21, 2026, as part of a pre-arranged plan to offset tax liabilities from vested restricted stock units. Concurrently, Karyopharm reported promising preliminary full-year 2025 financial results, highlighted by $145 million in tot…